Trial Profile
A Phase 1/2 Double Blind, Placebo Controlled, Randomized, Dose Ranging, Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CAT-192 Human Anti-TGF-Beta1 Monoclonal Antibody in Patients With Early Stage Diffuse Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Metelimumab (Primary)
- Indications Scleroderma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genzyme Corporation
- 05 Jun 2014 New trial record